Medicure Inc
Research Medicure Inc (MPH) on Bullrun: market cap CAD 13.36M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerMPH
- ExchangeV
- CountryCanada
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyCAD
- Market capCAD 13.36M
- Financial periodQ1 2026
- RevenueCAD 7.95M
- Net income-CAD 406.00K
- Free cash flow-CAD 1.83M
- Gross margin44.3%
Valuation Snapshot
latest market cap is CAD 13.36M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CAD 28.86M | -CAD 7.10M | -CAD 560.00K | 40.7% | n/a | CAD 3.84M | CAD 891.00K | CAD 12.91M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-23 | CAD 13.36M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 CAD.
About Medicure Inc
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing MC-1 for the treatment of PNPO deficiency;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Medicure Inc's market cap?
Medicure Inc's market capitalization is CAD 13.36M.
What does Medicure Inc do?
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing MC-1 for the treatment of PNPO deficiency; and TARDOXAL for neurological indications, such as Tardive Dyskinesia.